Provider review
Teleios Health review
One site-wide entry figure, and neither molecule card carries a price.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
From $99/mo, both molecules at the same figure
Visit Teleios HealthThe semaglutide and tirzepatide cards describe the drug in detail and attach no figure at all.
Price as published
Teleios Health
From $99/mo, both molecules at the same figure
- Vs median
- $76/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
A single low figure is doing all the work on this page. It appears in the hero and in every section header, and it is the only dollar amount anywhere on the site — which makes it read less like the price of a product and more like a slogan the site is built around. That is not a criticism of the number, which is genuinely at the low end of what this market charges and is at least stated as a proper monthly rate rather than a supply block or a divided prepay. It is a caution about what it attaches to. Both molecules get their own card, each describing the drug and its mechanism in reasonable detail, and neither card carries a price. So the figure floats free of any particular product: it is the cheapest thing available under some configuration the site does not describe, and choosing between the single agonist and the dual one — which cost a seller meaningfully different amounts to compound — you have nothing to tell you what either would actually cost. Everything is a floor, with no ceiling published anywhere, and no dose behind it.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want a low entry figure stated as a genuine monthly rate you can compare
- You want both molecules available from one physician-led practice
- You are starting out and want the lowest possible entry cost
Look elsewhere if
- You want a price attached to the molecule you would take. Neither card carries one
- You need a ceiling. Every figure here is a floor
- You want a dose behind the number. None is published
What it actually costs
Price as published
From $99/mo, both molecules at the same figure
- Vs median
- $76/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. The entry price is among the lower ones here and is stated as a proper monthly rate rather than a supply block or a divided prepay, so it compares directly against the rest of this market. Neither molecule card carries a price. That figure is the only dollar amount on the site, repeated in the hero and every section header, while the semaglutide and tirzepatide cards describe the drug and attach no price. So nothing is priced per molecule, and if you are choosing between a single and a dual agonist, which cost a seller meaningfully different amounts to compound, you have nothing to weigh. Every price is a floor with no ceiling, and no dose is published.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- The entry figure is among the lower ones published anywhere here.
- It is stated as a monthly rate rather than a block, so it compares directly.
- Both molecules are named and care is described as physician-led.
Pharmacy, labs and oversight
Teleios Health does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Teleios Health publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
A single low figure is doing all the work on this page. It appears in the hero and in every section header, and it is the only dollar amount anywhere on the site — which makes it read less like the price of a product and more like a slogan the site is built around. That is not a criticism of the number, which is genuinely at the low end of what this market charges and is at least stated as a proper monthly rate rather than a supply block or a divided prepay. It is a caution about what it attaches to. Both molecules get their own card, each describing the drug and its mechanism in reasonable detail, and neither card carries a price. So the ninety-nine dollars floats free of any particular product: it is the cheapest thing available under some configuration the site does not describe, and a reader choosing between the single agonist and the dual one — which cost a seller meaningfully different amounts to compound — has nothing to tell them what either would actually cost. Everything is a floor, with no ceiling published anywhere, and no dose sits behind the figure.
The honest cons
Neither molecule card carries a price; one site-wide figure covers everything.
- Every price is a floor, with no ceiling published anywhere.
- No dose sits behind the figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Teleios Health is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way Teleios Health does. Both are partners: we may earn a commission if you start care through these links.
Partner
Sprout Health
$149 sema · $199 tirz
Standard plan, self-directed low dose
FDA warning letter · Sprout Health · September 2025 · addressed to Sprout Health Partners LLC dba Sprout Health. Details in our review.
Partner
Bodybuilding Health+
$179/mo sema · $209/mo tirz
Standard plan, self-directed low dose
Where this sits
#285 of 548
Ordered with the companies that pay us first, and Teleios Health is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Microdosing tirzepatide
- Microdosing semaglutide
- The true annual cost of a plan
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Strut Health
$99/mo sema lozenge (auto-refill)
FDA warning letter · Strut Health · February 2026 · addressed to Strut Health, LLC dba Strut. Details in our review.
- Vs median
- $76/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Strut Health review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.